Are Green Bonds good investment option for long term retail Investors?

Are Green Bonds good investment option for long term retail Investors?

ByMarketFacts

Green Bonds is a type of fixed income security issued to raise money for climate & environmental projects. Like any other type of bond, green bonds offer a stated return and represent a loan from an investor to a company, organization, or government agency.

Green bonds may come with tax incentives such as tax exemption and tax credits, making them a more attractive investment vs. a comparable taxable bond. Investors interested in green bonds should learn the diverse types and the pros and cons of investing before buying.

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

With Douglas Elliman (NYSE: DOUG) going ex- dividend is there a room to get bullish on housing ?

ByMarketFacts

Douglas Elliman Inc. (XYNS: DOUG) is a real estate company. Among other real estate-related services, it provides sales, rentals, and new development in combination with mortgages and title insurance. The company operates in two divisions: Real Estate Brokerage and Corporate and Other. The company makes revenue from Commission and other brokerage income from existing house sales, Commission and other brokerage income from development marketing, Property management income, and Title fees. 

Are Novavax’s protein technology Covid shots & omicron-fighting prototype worth Investing : Novavax, Inc. (NASDAQ: NVAX) ?

Are Novavax’s protein technology Covid shots & omicron-fighting prototype worth Investing : Novavax, Inc. (NASDAQ: NVAX) ?

ByMarketFacts

Novavax, Inc (NASDAQ: NVAX) is a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Prior to 2020, company developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases.